-
公开(公告)号:US20050182103A1
公开(公告)日:2005-08-18
申请号:US10508043
申请日:2003-03-24
申请人: Paul Finke , Laura Meurer , John Debenham , Richard Toupence , Thomas Walsh
发明人: Paul Finke , Laura Meurer , John Debenham , Richard Toupence , Thomas Walsh
IPC分类号: C07D213/64 , A61K31/44 , A61K31/4418 , A61K31/4439 , A61K31/4545 , A61K31/455 , A61K31/496 , A61K31/5377 , A61K45/00 , A61K47/02 , A61K47/10 , A61K47/26 , A61K47/34 , A61P1/04 , A61P1/10 , A61P1/16 , A61P3/04 , A61P9/00 , A61P11/06 , A61P25/00 , A61P25/06 , A61P25/08 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/28 , A61P25/30 , A61P29/00 , A61P43/00 , C07D213/56 , C07D213/65 , C07D213/79 , C07D213/80 , C07D213/81 , C07D213/82 , C07D213/85 , C07D213/86 , C07D213/87 , C07D401/12 , C07D41/02
CPC分类号: C07D213/79 , C04B35/632 , C07D213/65 , C07D213/80 , C07D213/81 , C07D213/82 , C07D213/85 , C07D213/86 , C07D213/87 , C07D401/12
摘要: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
摘要翻译: 结构式(I)的新型化合物是大麻素-1(CB1)受体的拮抗剂和/或反向激动剂,可用于治疗,预防和抑制由CB1受体介导的疾病。 本发明的化合物可用作治疗精神病,记忆缺陷,认知障碍,偏头痛,神经病,包括多发性硬化和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症,脑血管 事故和头部创伤,焦虑障碍,压力,癫痫,帕金森病,运动障碍和精神分裂症。 这些化合物还可用于治疗药物滥用障碍,治疗肥胖或进食障碍,以及治疗哮喘,便秘,慢性肠假性梗阻和肝硬化。
-
公开(公告)号:US20050272763A1
公开(公告)日:2005-12-08
申请号:US10521821
申请日:2003-08-01
申请人: Richard Toupence , John Debenham , Mark Goulet , Christina Madsen-Duggan , Thomas Walsh , Shrenik Shah
发明人: Richard Toupence , John Debenham , Mark Goulet , Christina Madsen-Duggan , Thomas Walsh , Shrenik Shah
IPC分类号: C07D491/048 , A61K31/00 , A61K31/4355 , A61K31/4375 , A61K31/444 , A61K31/4545 , A61K31/4741 , A61K31/496 , A61K31/5377 , A61P1/00 , A61P1/10 , A61P1/16 , A61P3/04 , A61P9/10 , A61P11/06 , A61P25/00 , A61P25/06 , A61P25/08 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/28 , A61P25/30 , A61P43/00 , C07D453/06 , C07D491/02 , C07D491/04 , C07D519/00
CPC分类号: C07D491/04 , C07D453/06
摘要: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
摘要翻译: 结构式(I)的新型化合物是大麻素-1(CB1)受体的拮抗剂和/或反向激动剂,可用于治疗,预防和抑制由CB1受体介导的疾病。 本发明的化合物可用作治疗精神病,记忆缺陷,认知障碍,偏头痛,神经病,包括多发性硬化和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症,脑血管 事故和头部创伤,焦虑症,压力,癫痫,帕金森病,运动障碍和精神分裂症。 这些化合物还可用于治疗药物滥用障碍,治疗肥胖或进食障碍,以及治疗哮喘,便秘,慢性肠假性梗阻和肝硬化。
-
公开(公告)号:US20060287290A1
公开(公告)日:2006-12-21
申请号:US11509381
申请日:2006-08-24
申请人: Michael Dart , Xenia Searle , Karin Tietje , Richard Toupence
发明人: Michael Dart , Xenia Searle , Karin Tietje , Richard Toupence
IPC分类号: C07D471/02 , A61K31/4745 , A61K31/4743 , A61K31/4741 , A61K31/426 , A61K31/433 , A61K31/42 , A61K31/4178 , A61K31/404 , A61K31/397
CPC分类号: C07D401/04 , C07D403/04 , C07D409/04 , C07D413/04 , C07D417/04 , C07D471/04 , C07D495/04
摘要: Compounds of formula (I) are novel CNS active agents that are useful for treating pain and for treating other disorders associated with the cholinergic system.
-
4.
公开(公告)号:US20080097094A1
公开(公告)日:2008-04-24
申请号:US11957424
申请日:2007-12-15
申请人: Michael Schrimpf , Karin Tietje , Richard Toupence , Jianguo Ji , Anwer Basha , William Bunnelle , Jerome Daanen , Jennifer Frost , Kevin Sippy
发明人: Michael Schrimpf , Karin Tietje , Richard Toupence , Jianguo Ji , Anwer Basha , William Bunnelle , Jerome Daanen , Jennifer Frost , Kevin Sippy
IPC分类号: A61K31/55 , A61K31/4353 , A61P25/00 , C07D471/04 , C07D487/04
CPC分类号: C07D471/04 , C07D487/04
摘要: Compounds of formula I pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.
摘要翻译: 式I化合物,这些化合物的药物组合物,以及所述组合物用于控制哺乳动物突触传递的用途。
-
-
-